Partnership-with-clicktherapeutics

Boehringer Ingelheim and Click Therapeutics Enter into Collaboration to Develop and Commercialize CT-155, a Novel Prescription Digital Therapeutic to Aid in the Treatment of Schizophrenia This collaboration combines Click Therapeutics ’ specialty in developing efficacious and engaging digital therapeutics with Boehringer Ingelheim’s expertise in clinical development of treatments for neuropsychiatric diseases, furthering Boehringer Ingelheim’s commitment to exploring digital innovations to benefit patients with unmet medica l needsTogether the companies will develop and commercialize a prescription-based digital therapeutic with the goal of helping schizophrenia patients achieve certain positive clinical outcomesBoehringer Ingelheim will receive exclusive global rights to CT-155; Click Therapeutics will receive an upfront payment, development funding, and is eligible to receive additional clinical, regulatory and commercial milestones for a total deal value to Click Therapeutics of over $500 million, plus tiered royalties
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news